Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a thymus hormone shield aortic dissection patients from organ failure?

NCT ID NCT05339529

Prevention Sponsor: Nanjing Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 14, 2026 · Last updated Sep 15, 2026 · Updated 1 time

Summary

People with acute aortic dissection face a high risk of dangerous inflammation and multiple organ failure after emergency surgery. Researchers are testing whether thymosin alpha 1, an immune-modulating injection, can reduce that risk. The trial enrolls 600 adults undergoing emergency surgery for acute aortic syndrome. Half receive thymosin alpha 1 every 12 hours during intensive care, and half receive standard care alone. The main measure is how well organs function over the first week after surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
thymosin alpha 1, an immune-modulating injection
What this could lead to
If it works, thymosin alpha 1 could become a standard immune-support treatment after emergency aortic dissection surgery, helping patients avoid organ failure and death.
What could go wrong
This is an early-phase study, so it may not show a clear benefit. Thymosin alpha 1 can cause allergic reactions, and the trial excludes people who are allergic to it.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

600 people

The number who actually took part.

Started

Jul 2022

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The patients are conformed to 2010 ACC/AHA guidelines for the diagnosis and treatment of thoracic aortic disease (TAD) within two weeks of onset; * Patients with acute aortic syndrome confirmed clinically and radiologically and planning to undergo emergency surgery were enrolled. * The patients' age between 18 \~90 years old. * Agree to participate in the study and sign the informed consent. Exclusion Criteria: * Patients allergic to Thymosin α1; * Lactating women and pregnant women; * Patients with mental diseases, drug and alcohol dependence; * Refuse to participate in this study and refuse to sign the informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute aortic syndrome are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Acute Aortic Syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute aortic syndrome Aortic dissection type A

Contacts and locations

Locations

  • Beijing Anzhen Hospital Capital Medical University

    Beijing, 10029, China

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China

  • Nanjing First Hospital Nanjing Medical University

    Nanjing, Jiangsu, China

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China

  • Shanghai East Hospital Tongji University

    Shanghai, China

  • Subei People's Hospital of Jiangsu Province

    Yangzhou, Jiangsu, China

  • TEDA International Cardiovascular Hospital

    Tianjin, China

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China

  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, China

  • The First Affiliated Hospital of Kunming Medical University

    Kunming, Yunnan, China

  • The First Affiliated Hospital of Nanjing Medical University

    Nanjing, Jiangsu, 210029, China

  • The Friendship Hospital of Yili Kazak Autonomous Prefecture

    Kazak, Xinjiang, China

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, China

  • The Seventh Affiliated Hospital of Xinjiang Medical University

    Ürümqi, Xinjiang, China

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.